Rigel Pharmaceuticals Inc - Asset Resilience Ratio
Rigel Pharmaceuticals Inc (RIGL) has an Asset Resilience Ratio of 24.23% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Rigel Pharmaceuticals Inc strategic capital allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2000–2025)
This chart shows how Rigel Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. See net asset quality index of Rigel Pharmaceuticals Inc to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Rigel Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Rigel Pharmaceuticals Inc (RIGL) market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $122.27 Million | 24.23% |
| Total Liquid Assets | $122.27 Million | 24.23% |
Asset Resilience Insights
- Good Liquidity Position: Rigel Pharmaceuticals Inc maintains a healthy 24.23% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Rigel Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare Rigel Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC |
Biotechnology | -55.36% |
|
Krystal Biotech Inc
NASDAQ:KRYS |
Biotechnology | 23.06% |
|
Verona Pharma PLC ADR
NASDAQ:VRNA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
BB Biotech AG
SW:BION |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for Rigel Pharmaceuticals Inc (2000–2025)
The table below shows the annual Asset Resilience Ratio data for Rigel Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 22.27% | $114.38 Million | $513.59 Million | +9.72pp |
| 2024-12-31 | 12.55% | $20.57 Million | $163.98 Million | -8.05pp |
| 2023-12-31 | 20.60% | $24.15 Million | $117.22 Million | -4.53pp |
| 2022-12-31 | 25.13% | $33.75 Million | $134.28 Million | -38.26pp |
| 2021-12-31 | 63.39% | $106.08 Million | $167.33 Million | +38.97pp |
| 2020-12-31 | 24.42% | $26.95 Million | $110.38 Million | -26.78pp |
| 2019-12-31 | 51.20% | $75.56 Million | $147.57 Million | +13.67pp |
| 2018-12-31 | 37.54% | $52.22 Million | $139.11 Million | -27.50pp |
| 2017-12-31 | 65.03% | $77.46 Million | $119.11 Million | -8.09pp |
| 2016-12-31 | 73.12% | $57.13 Million | $78.13 Million | +10.26pp |
| 2015-12-31 | 62.86% | $82.82 Million | $131.75 Million | -20.15pp |
| 2014-12-31 | 83.02% | $127.96 Million | $154.13 Million | -1.53pp |
| 2013-12-31 | 84.55% | $191.12 Million | $226.06 Million | -0.85pp |
| 2012-12-31 | 85.39% | $264.76 Million | $310.04 Million | -3.68pp |
| 2011-12-31 | 89.07% | $229.01 Million | $257.11 Million | -1.14pp |
| 2010-12-31 | 90.21% | $168.42 Million | $186.69 Million | +5.94pp |
| 2009-12-31 | 84.27% | $118.60 Million | $140.74 Million | +22.77pp |
| 2008-12-31 | 61.50% | $88.47 Million | $143.86 Million | +6.41pp |
| 2007-12-31 | 55.09% | $63.79 Million | $115.79 Million | +4.98pp |
| 2006-12-31 | 50.11% | $56.74 Million | $113.24 Million | +8.52pp |
| 2005-12-31 | 41.59% | $61.42 Million | $147.67 Million | -35.71pp |
| 2004-12-31 | 77.30% | $60.93 Million | $78.82 Million | +10.88pp |
| 2003-12-31 | 66.42% | $36.88 Million | $55.52 Million | +64.71pp |
| 2002-12-31 | 1.70% | $756.00K | $44.34 Million | -45.50pp |
| 2001-12-31 | 47.21% | $21.93 Million | $46.45 Million | +41.04pp |
| 2000-12-31 | 6.17% | $3.96 Million | $64.26 Million | -- |
About Rigel Pharmaceuticals Inc
Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relap… Read more